Recent Progress in Multiple Sclerosis Treatment Using Immune Cells as Targets

被引:8
|
作者
Ma, Xiaohong [1 ,2 ]
Ma, Rong [3 ]
Zhang, Mengzhe [3 ]
Qian, Baicheng [1 ]
Wang, Baoliang [1 ]
Yang, Weijing [3 ]
机构
[1] Henan Univ Chinese Med, Affiliated Hosp 1, Dept Neurosci, Zhengzhou 450000, Peoples R China
[2] Henan Univ Chinese Med, Clin Med Sch 1, Zhengzhou 450046, Peoples R China
[3] Zhengzhou Univ, Sch Pharmaceut Sci, Henan Key Lab Targeting Therapy & Diag Crit Dis, Zhengzhou 450001, Peoples R China
基金
中国国家自然科学基金;
关键词
multiple sclerosis; immunotherapy; T cells; B cells; innate immune cells; REGULATORY T-CELLS; PLACEBO-CONTROLLED TRIAL; MYELIN BASIC-PROTEIN; GLATIRAMER ACETATE; B-CELLS; DENDRITIC CELLS; DOUBLE-BLIND; IFN-BETA; MENINGEAL INFLAMMATION; NEUROMYELITIS-OPTICA;
D O I
10.3390/pharmaceutics15030728
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Multiple sclerosis (MS) is an autoimmune-mediated demyelinating disease of the central nervous system. The main pathological features are inflammatory reaction, demyelination, axonal disintegration, reactive gliosis, etc. The etiology and pathogenesis of the disease have not been clarified. The initial studies believed that T cell-mediated cellular immunity is the key to the pathogenesis of MS. In recent years, more and more evidence has shown that B cells and their mediated humoral immune and innate immune cells (such as microglia, dendritic cells, macrophages, etc.) also play an important role in the pathogenesis of MS. This article mainly reviews the research progress of MS by targeting different immune cells and analyzes the action pathways of drugs. The types and mechanisms of immune cells related to the pathogenesis are introduced in detail, and the mechanisms of drugs targeting different immune cells are discussed in depth. This article aims to clarify the pathogenesis and immunotherapy pathway of MS, hoping to find new targets and strategies for the development of therapeutic drugs for MS.
引用
收藏
页数:20
相关论文
共 50 条
  • [21] Progress in determining the causes and treatment of multiple sclerosis
    John H. Noseworthy
    Nature, 1999, 399 : A40 - A47
  • [22] Emerging immune targets for the treatment of multiple myeloma
    Sohail, Atif
    Mushtaq, Adeela
    Iftikhar, Ahmad
    Warraich, Zabih
    Kurtin, Sandra E.
    Tenneti, Pavan
    McBride, Ali
    Anwer, Faiz
    IMMUNOTHERAPY, 2018, 10 (04) : 265 - 282
  • [23] Emerging Immune Targets for Treatment of Multiple Myeloma
    Sohail, Atif
    Mushtaq, Adeela
    Iftikhar, Ahmad
    Latif, Azka
    Kapoor, Vikas
    Warraich, Faiza Hassan
    Warraich, Sami Ullah
    Baig, Mirza Zeeshan
    McBride, Ali
    Anwer, Faiz
    BLOOD, 2017, 130
  • [24] Targeting B cells in the treatment of multiple sclerosis: recent advances and remaining challenges
    Lehmann-Horn, Klaus
    Kronsbein, Helena C.
    Weber, Martin S.
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2013, 6 (03) : 161 - 173
  • [25] Multiple Myeloma : Recent Progress in Diagnosis and Treatment
    Chou, Takaaki
    JOURNAL OF CLINICAL AND EXPERIMENTAL HEMATOPATHOLOGY, 2012, 52 (03) : 149 - 159
  • [26] Neurotrophic factor production by immune cells during testosterone treatment in multiple sclerosis
    Gold, S. M.
    Giesser, B. S.
    Voskuhl, R. R.
    MULTIPLE SCLEROSIS, 2007, 13 : S148 - S149
  • [27] Glial cells as therapeutic targets in progressive multiple sclerosis
    Wilbanks, Brandon
    Maher, L. J., III
    Rodriguez, Moses
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2019, 19 (06) : 481 - 494
  • [28] Role of innate immune cells in multiple sclerosis
    Prado, Carolina
    Herrada, Andres A.
    Hevia, Daniel
    Goiry, Lorna Galleguillos
    Escobedo, Noelia
    FRONTIERS IN IMMUNOLOGY, 2025, 16
  • [29] Mast cells: new targets for multiple sclerosis therapy?
    Zappulla, JP
    Arock, M
    Mars, LT
    Liblau, RS
    JOURNAL OF NEUROIMMUNOLOGY, 2002, 131 (1-2) : 5 - 20
  • [30] Immune mechanisms and treatment perspectives in multiple sclerosis
    Hohlfeld, R
    INTRAVENOUS IMMUNOGLOBULINS IN THE THIRD MILLENNIUM, 2004, : 221 - 228